ICD-10 Logo
ICDxICD-10 Medical Coding
ICD-10 Logo
ICDxICD-10 Medical Coding
ICD 10 CodesDiagnoses
ICD 10 CodesDiagnoses
ICD-10 Logo
ICDxICD-10 Medical Coding

Comprehensive ICD-10-CM code reference with AI-powered search capabilities.

© 2025 ICD Code Compass. All rights reserved.

Browse

  • All Chapters
  • All Categories
  • Diagnoses

Tools

  • AI Code Search
ICD-10-CM codes are maintained by the CDC and CMS. This tool is for reference purposes only.
v1.0.0
ICD-10 Guide
ICD-10 CodesChapter 2: NeoplasmsD07

D07

Billable

Carcinoma in situ of other and unspecified genital organs

Chapter 2:Neoplasms

BILLABLE STATUSYes
IMPLEMENTATION DATEOctober 1, 2015
LAST UPDATED09/05/2025

Code Description

ICD-10 D07 is a billable code used to indicate a diagnosis of carcinoma in situ of other and unspecified genital organs.

Key Diagnostic Point:

Carcinoma in situ (CIS) of the genital organs refers to a localized cancerous condition where abnormal cells are present but have not invaded surrounding tissues. This diagnosis is critical as it indicates a pre-invasive stage of cancer, which can potentially progress to invasive cancer if left untreated. The term 'other and unspecified genital organs' encompasses various sites within the genital region, including the vulva, vagina, cervix, and other less common sites. Surveillance protocols for patients diagnosed with D07 typically involve regular gynecological examinations, Pap smears, and possibly colposcopy to monitor for any changes in the cellular structure. The risk of progression to invasive cancer varies depending on the specific site of the carcinoma, the patient's age, and other risk factors such as HPV infection. Early detection and intervention are crucial in managing this condition effectively, as timely treatment can prevent the development of invasive cancer.

Code Complexity Analysis

Complexity Rating: Medium

Medium Complexity

Complexity Factors

  • Variety of sites included under 'other and unspecified genital organs'
  • Need for precise documentation of the site and type of carcinoma
  • Potential overlap with other codes for invasive cancers
  • Variability in treatment protocols based on the site and patient history

Audit Risk Factors

  • Inadequate documentation of the specific site of carcinoma
  • Failure to document the patient's treatment plan and follow-up
  • Misclassification of carcinoma in situ as invasive cancer
  • Lack of clear staging and grading information

Specialty Focus

Medical Specialties

Gynecology

Documentation Requirements

Detailed documentation of the diagnosis, site, treatment plan, and follow-up care.

Common Clinical Scenarios

Routine screenings, abnormal Pap results, and follow-up after treatment.

Billing Considerations

Ensure that all findings from examinations and biopsies are clearly documented to support the diagnosis.

Oncology

Documentation Requirements

Comprehensive treatment plans, including surgical, medical, and radiation therapy details.

Common Clinical Scenarios

Management of patients with a history of carcinoma in situ and monitoring for progression.

Billing Considerations

Documentation should include any multidisciplinary team discussions and decisions regarding treatment.

Coding Guidelines

Inclusion Criteria

Use D07 When
  • According to ICD
  • 10 coding guidelines, D07 should be used when the carcinoma is confirmed as in situ and the specific site is documented
  • It is important to differentiate between in situ and invasive carcinoma to ensure accurate coding

Exclusion Criteria

Do NOT use D07 When
No specific exclusions found.

Related CPT Codes

88141CPT Code

Cytopathology, cervical or vaginal (Pap smear)

Clinical Scenario

Used for routine screening in patients at risk for carcinoma in situ.

Documentation Requirements

Document the reason for the Pap smear and any abnormal findings.

Specialty Considerations

Gynecologists should ensure follow-up protocols are in place for abnormal results.

ICD-10 Impact

Diagnostic & Documentation Impact

Enhanced Specificity

ICD-10 Improvements

The transition to ICD-10 has allowed for more specific coding of carcinoma in situ, improving the accuracy of data collection and treatment tracking. D07 provides a clearer distinction between in situ and invasive cancers, which is crucial for treatment planning and epidemiological studies.

ICD-9 vs ICD-10

The transition to ICD-10 has allowed for more specific coding of carcinoma in situ, improving the accuracy of data collection and treatment tracking. D07 provides a clearer distinction between in situ and invasive cancers, which is crucial for treatment planning and epidemiological studies.

Reimbursement & Billing Impact

The transition to ICD-10 has allowed for more specific coding of carcinoma in situ, improving the accuracy of data collection and treatment tracking. D07 provides a clearer distinction between in situ and invasive cancers, which is crucial for treatment planning and epidemiological studies.

Resources

Clinical References

  • •
    ICD-10-CM Official Guidelines for Coding and Reporting

Coding & Billing References

  • •
    ICD-10-CM Official Guidelines for Coding and Reporting

Frequently Asked Questions

What is the difference between carcinoma in situ and invasive carcinoma?

Carcinoma in situ refers to abnormal cells that have not invaded surrounding tissues, while invasive carcinoma has spread beyond the original site into nearby tissues.